作为HNF1B-MODY的潜在治疗替代品的塞马格卢提德:一个案例研究
Angham Almutair1,2,3, Beshaier Almulhem1,2,4
1Pediatric Department, King Abdullah Specialized Children's Hospital, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Frontiers in endocrinology
|March 25, 2024
概括
作为GLP-1RA的一种,塞马格卢提德通过改善血糖控制和减少胰岛素依赖,在治疗HNF1B-MODY糖尿病方面表现有前途. 然而,副作用导致治疗中止,突出了进一步研究的必要性.
科学领域:
- 内分泌学和新陈代谢学
- 遗传学和基因组学 在
- 药理学 药理学是指药理学的学科.
背景情况:
- 年轻人成熟期糖尿病 (MODY) 包括罕见的单一性糖尿病形式.
- 特定的亚型HNF1B-MODY通常需要胰岛素,但缺乏针对性的精确治疗.
- 本案例研究侧重于一个18岁的女性,患有HNF1B-MODY,基因缺失,囊和低磁性血症.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...